CAMP4 Therapeutics Corp
NASDAQ:CAMP
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CAMP4 Therapeutics Corp
Sachanlagen brutto
CAMP4 Therapeutics Corp
Sachanlagen brutto Peer-Vergleich
CAMP4 Therapeutics Corp
Kurzansicht
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company is headquartered in Cambridge, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2024-10-11. The company is leveraging its RAP Platform to advance a pipeline of programs initially focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
Auch interessant
Wie hoch ist Sachanlagen brutto von CAMP4 Therapeutics Corp?
Sachanlagen brutto
2.8m
USD
Laut Finanzbericht vom Dec 31, 2025 beträgt Sachanlagen brutto von CAMP4 Therapeutics Corp 2.8m USD.
Wie hoch ist die Wachstumsrate von Sachanlagen brutto bei CAMP4 Therapeutics Corp?
Sachanlagen brutto CAGR 3J
-45%
Im letzten Jahr lag das Wachstum von Sachanlagen brutto bei -73%. Die durchschnittlichen jährlichen Wachstumsraten von Sachanlagen brutto bei CAMP4 Therapeutics Corp lagen bei -45% über die letzten drei Jahre .
